Immune-modulating, clinical-stage product candidates targeting underserved conditions and offering the potential for differentiation.
Pipeline
PROGRAM & TARGET
Cardiovascular Franchise
ARCALYST®
(rilonacept)1,2
PHASE: COMMERCIAL
(Excluding MENA)
PROGRAM & TARGET
Cardiovascular Franchise
Mavrilimumab3
PHASE: 1
PROGRAM & TARGET
Autoimmune Franchise
KPL-404
PHASE: 2
OSMRβ
1 Approved in the U.S; ARCALYST is also approved for cryopyrin-associated periodic syndromes (CAPS) and deficiency of the interleukin-1 receptor antagonist (DIRA);
2 The FDA granted Breakthrough Therapy designation to ARCALYST for recurrent pericarditis in 2019; the FDA granted Orphan Drug exclusivity to ARCALYST in March 2021 for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and pediatric patients 12 years and older. The European Commission granted Orphan Drug designation to ARCALYST for the treatment of idiopathic pericarditis in 2020;
3 Phase 2 clinical trials of mavrilimumab in rheumatoid arthritis and giant cell arteritis achieved their primary and secondary endpoints with statistical significance;
4 Kiniksa granted Huadong Medicine exclusive rights in the Asia Pacific Region, excluding Japan;
5 In September 2022, Kiniksa granted Genentech and Roche exclusive global rights to develop and commercialize vixarelimab;
IL-1α = interleukin-1α ; IL-1β = interleukin-1β; GM-CSFRα = granulocyte macrophage colony stimulating factor receptor alpha; OSMRβ = oncostatin M receptor beta; MENA = Middle East and North Africa.